Aiforia selected as partner for Sardinia’s regional health authority

Translation: Original published in Finnish on 3/7/2025 at 7:00 am EET.

Aiforia announced that the Sardinian region health authorities in Italy have selected the company as their partner for image analysis for clinical diagnostics in pathology. The collaboration covers the use of Aiforia's clinical AI solutions for the analysis of breast and prostate cancer biopsies. Sardinia is a separate island and one of Italy's smallest provinces in terms of population, with approximately 1.6 million inhabitants.

While the release did not disclose the commercial value of the collaboration, we estimate it to be significantly smaller than the agreements made with Veneto (estimated at 0.3–0.4 MEUR annually) and Lombardy (estimated at 0.5–1.0 MEUR annually). Sardinia has a clearly smaller population than these regions, and the scope of the agreement is also smaller at this point. For example, the Lombardy agreement covered the use of Aiforia's clinical AI solutions for the analysis of breast, lung and prostate cancer biopsies and Aiforia's AI model development software.

The two-year contract is part of a procurement of seven hospitals in the region, which aims to improve the diagnostic workflow of the region's pathology laboratories. The provider in the deal is a GPI S.p.A. lead consortium (the same as for Veneto and Lombardy), and Aiforia is one of their subcontractors. The company announced last fall that it was participating in 15 tenders in Italy alone, and this news comes as no surprise given its success in previous tenders. However, the agreement is further proof of the company's good competitiveness. Our forecasts include continuous customer wins, so the news does not put immediate pressure to change our forecasts. The company will present its H2’24 report today, Friday, and our preview can be read here.